Core Viewpoint - Curis, Inc. is making significant progress in its clinical programs, particularly with emavusertib, an IRAK4 inhibitor, showing promising results in combination therapies for various cancers, setting a positive outlook for 2025 [2][3]. Clinical Developments - Emavusertib demonstrated efficacy in a study involving patients with relapsed/refractory primary central nervous system lymphoma (PCNSL), with 3 complete responses and 1 unconfirmed complete response among 10 evaluable patients [3]. - The company plans to present additional clinical data from the TakeAim Leukemia study at the upcoming ASH annual meeting [4][5]. Financial Performance - For Q3 2024, Curis reported a net loss of $10.1 million, or $1.70 per share, an improvement from a net loss of $12.2 million, or $2.13 per share, in Q3 2023 [6]. - Revenues for Q3 2024 were $2.9 million, slightly up from $2.8 million in the same period last year, primarily from royalty revenues [7]. - Research and development expenses decreased to $9.7 million in Q3 2024 from $10.4 million in Q3 2023, attributed to lower consulting and employee-related costs [8]. Cash Position - Following a recent offering, Curis's cash and cash equivalents totaled $31.6 million, which is expected to support operations into mid-2025 [11].

LEXINGTON, Mass., Nov. 7, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2024 financial and operating results on Thursday, November 14, 2024, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET.Participants may join by dialing (800)-836-8184 from the Unite ...

LEXINGTON, Mass., Oct. 29, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that it has entered into a definitive agreement with a combination of existing and new investors for the purchase of 2,398,414 shares of its common stock in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Curis also agreed ...

Symposium hosted by Eric S. Winer, MD, and Grzegorz S. Nowakowski, MD Updated data for 10 evaluable patients in Curis's PCNSL study Experts will present at the virtual meeting, free and open to the public, on September 26, 2024 LEXINGTON, Mass., Sept. 23, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced the 3rd Annual Symposium on IRAK4 in Cancer taking place virt ...

LEXINGTON, Mass., Sept. 17, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate in a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference later today at 4:15 PM ET. Details for the webcast can be found using the Cantor webcast link. The webcast will be also availa ...

LEXINGTON, Mass., Sept. 4, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences: The H.C. Wainwright 26th Annual Global Investment Conference being held September 9 – 11, 2024. Presentation details are as follows: Format: Company Presentation Date: Wednesd ...

Curis, Inc. (NASDAQ:CRIS) Q2 2024 Earnings Conference Call August 1, 2024 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer Jim Dentzer - President and CEO Jonathan Zung - Chief Development Officer Conference Call Participants Yale Jen - Laidlaw Ed White - H.C. Wainwright Soumit Roy - JonesTrading Li Watsek - Cantor Operator Good morning, ladies and gentlemen. And welcome to the Curis Provides Second Quarter 2024 Business Update Conference Call. At this time, all lines are in listen-o ...

Curis (CRIS) came out with a quarterly loss of $2.03 per share versus the Zacks Consensus Estimate of a loss of $1.70. This compares to loss of $2.40 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -19.41%. A quarter ago, it was expected that this drug developer would post a loss of $1.94 per share when it actually produced a loss of $2.05, delivering a surprise of -5.67%. Over the last four quarters, the company has surpasse ...

Table of Contents Title of each class Trading Symbol Name of each exchange on which registered UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-30347 CURIS, INC. (Exact Name o ...

Exhibit 99.1 PRESS RELEASE Curis Provides Second Quarter 2024 Financial and Operating Update EC Grants ODD to emavusertib in PCNSL Management to host conference call and webcast today at 8:30 a.m. ET LEXINGTON, Mass., August 1, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its financial and operating results for the second quarter ended June 30, 2024. Operationa ...